Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Origin, fate and dynamics of macrophages at central nervous system interfaces.
Webinar: Solutions for Genome Editing: TALEN, CRISPR, & Safe Harbor Integration
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
Effects of dimethyl fumarate on neuroprotection and immunomodulation.
Episode 30 with Dr. Seema Tiwari-Woodruff on estrogenic compounds and MS
Quantifying the early stages of remyelination following cuprizone-induced demyelination.
TECFIDERA prescribing information
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
Sex differences in autoimmune diseases.
IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients
Optical coherence tomography reflects brain atrophy in MS: A four year study.
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
Keystone Symposium: Gut Microbiota Modulation of Host Physiology: The Search for Mechanism
The neuroendocrine axis in patients with multiple sclerosis.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response.
Episode 4 with Dr. Michael Racke on the Kir4.1 potassium channel
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
American Academy of Neurology: Breakthroughs in Neurology
ACRM I American Congress of Rehabilitation
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.
Pages
« first
‹ previous
…
52
53
54
55
56
57
58
59
60
…
next ›
last »